Atara Biotherapeutics Inc
Research Atara Biotherapeutics Inc (ATRA) on Bullrun: market cap USD 92.92M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerATRA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 92.92M
- Financial periodQ1 2026
- RevenueUSD 516.00K
- Net income-USD 4.15M
- Free cash flow-USD 3.07M
- Gross margin76.0%
Valuation Snapshot
latest market cap is USD 92.92M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 120.77M | USD 32.69M | -USD 50.94M | 82.4% | 2.57 | USD 8.48M | USD 10.38M | -USD 38.50M |
| FY2024 | USD 128.94M | -USD 85.40M | -USD 68.96M | 83.7% | -11.41 | USD 25.03M | USD 43.83M | -USD 97.28M |
| FY2023 | USD 8.57M | -USD 276.13M | -USD 194.20M | n/a | -65.19 | USD 25.84M | USD 57.87M | USD 99.23M |
| FY2022 | USD 63.57M | -USD 228.30M | -USD 274.62M | n/a | -2.24 | USD 92.94M | USD 64.00M | USD 126.64M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 92.92M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 132.49M | 6.2 | n/a | n/a |
| 2024 | 2024-12-31 | USD 77.98M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 52.27M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 311.20M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.44B | n/a | n/a | n/a |
About Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Atara Biotherapeutics Inc's market cap?
Atara Biotherapeutics Inc's market capitalization is USD 92.92M.
What does Atara Biotherapeutics Inc do?
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases.